Metabolife 356 “Unreasonably Dangerous,” Jury Says In $4.1 Mil. Verdict
This article was originally published in The Tan Sheet
Executive Summary
Metabolife sold its ephedrine alkaloid-containing Metabolife 356 in a "defective condition unreasonably dangerous to an ultimate user," a Birmingham, Ala. federal jury concluded in four cases Nov. 19
You may also be interested in...
Metabolife Liability Reversal Offers Precedent For Ephedra Defendants
Defendants' prospects in future ephedra liability suits may have been strengthened by a FDL-1federal appeals court reversal of a $4.1 mil. jury award against Metabolife
Metabolife Liability Reversal Offers Precedent For Ephedra Defendants
Defendants' prospects in future ephedra liability suits may have been strengthened by a FDL-1federal appeals court reversal of a $4.1 mil. jury award against Metabolife
Metabolife Liability Reversal Offers Precedent For Ephedra Defendants
Defendants' prospects in future ephedra liability suits may have been strengthened by a FDL-1federal appeals court reversal of a $4.1 mil. jury award against Metabolife